Research is often lauded for finding life-saving treatments for diseases like cancer or diabetes. But consider the impact of preventing such illnesses from developing in the first place. It’s hard to describe the value of stopping illness or injury from happening. Yet that’s the goal of research on preventive care.
Most Kaiser Permanente Washington scientists study prevention, whether their work focuses on promoting health by influencing individual behavior, building sound prevention services into everyday clinical care, designing smart health coverage, or all three. By conducting their research at Kaiser Permanente Washington—which combines care and coverage—our researchers have access to data from a large, stable population over time, allowing them to discover which approaches to prevention work best.
Examples include research in areas such as:
A team of researchers at Kaiser Permanente Washington Health Research Institute (KPWHRI) produces reviews of scientific evidence that policymakers at the Centers for Medicare & Medicaid Services and the U.S. Preventive Services Task Force and others use in health care decision-making. We do this work as part of the Kaiser Permanente Research Affiliates Evidence-based Practice Center, one of 13 centers nationwide that are sponsored by the federal Agency for Healthcare Research and Quality.
We’re improving the safety and effectiveness of vaccines through clinical trials, and we’re monitoring how well each year’s new flu vaccines are working. In addition, we’re studying ways to better inform parents about the benefits and potential harms of childhood vaccines, to improve their uptake.
We’re working on several fronts to help ensure the safety of prescription drugs and other medical treatments. For example, we play a leading role in the Food and Drug Administration’s Sentinel program to monitor the safety of medical products through routinely collected electronic health care data. We’re exploring ways to improve the safety of prescribing opioid pain medications. And we often study the safety of drugs commonly used to prevent chronic conditions like heart disease, cancer, and depression.
Prevention also includes screening to detect disease before symptoms appear, to identify and treat disease at an earlier stage. Our research is improving the effectiveness of cancer screening programs so people get the appropriate tests when needed based on their particular risks. Our research is also aimed at improving clinical screening for behavioral risks such as smoking, suicidal thoughts, alcohol use disorders, and poor eating and exercise habits.
Our research in areas such as smoking cessation, healthy diet, and chronic illness care finds new ways to encourage individuals to adopt and maintain healthier lifestyles. At the same time, we’re exploring ways to reach large populations through the use of phone-based programs, websites, and mobile technologies.
Simon GE, Wellman R, Shortreed SM, Johnson E, Sterling SA, Coleman KJ, Ahmedani BK, Yaseen ZS, Mosholder AD Predicting and differentiating opioid and non-opioid drug poisonings using health records data 2026 Mar;182:209861 doi:10.1016/j.josat.2025.209861. doi: 10.1016/j.josat.2025.209861. Epub 2025-12-22. PubMed
Binswanger IA, Yu O, Wartko PD, Addis M, Bobb JF, Lee AK, Yarborough BJ, Arnsten J, Glass JE, Northrup TF, Murphy M, Braciszewski JM, Horigian VE, Shoup JA, Potter A, Bradley KA Variability in medication treatment of opioid use disorder in primary care: Comparison of PROUD trial intervention clinics and other exemplar clinics 2026 Jan 16 doi: 10.1016/j.josat.2026.209896. Epub 2026-01-16. PubMed
Matson TE, Lee AK, Williams EC Structural Approaches to Expand Access to Medication Treatment for Alcohol Use Disorder 2026 Jan 2;9(1):e2551544. doi: 10.1001/jamanetworkopen.2025.51544. Epub 2026-01-02. PubMed
Matson TE, Johnson E, Bobb JF, Graham VF, Kiel LM, Lee AK, Lapham GT, Caldeiro RM, Bradley KA, Angerhofer JE Implementing Care for Cannabis and Other Drug Use in Adult Primary Care: Outcomes of a Cluster-Randomized Implementation Trial 2026 Jan;70(1):108112 doi:10.1016/j.amepre.2025.108112. doi: 10.1016/j.amepre.2025.108112. Epub 2025-09-16. PubMed
Wong ES, Dorsey CN, Beatty TC, Bobb JF, Stefanik-Guizlo K, Key DL, Ramaprasan A, Idu AE, Fortney JC, Mogk J, Palazzo L, Caldeiro RM, King D, McWethy AG, Glass JE Economic cost of strategic implementation approaches to increase uptake of digital therapeutics for substance use disorders in a large integrated health system 2026 Jan;5(1):e0001145. doi: 10.1371/journal.pdig.0001145. Epub 2026-01-08. PubMed
Julie Angerhofer, PhD, MPHAssociate Investigator |
Jennifer F. Bobb, PhDSenior Biostatistics Investigator |
Katharine A. Bradley, MD, MPHSenior Investigator |
Clarissa Hsu, PhDAssociate Investigator |
Noorie Hyun, PhDAssociate Biostatistics Investigator |
Morgan Justice, PhD, MASenior Collaborative Scientist |
Gwen Lapham, PhD, MPH, MSWAssociate Investigator |
Theresa E. Matson, PhD, MPHCollaborative Scientist |
Jess Mogk, MPHCollaborative Scientist |
Yu-Ru Su, PhDAssociate Biostatistics Investigator |
Paige D. Wartko, PhD, MPHSenior Collaborative Scientist |